Barrier Therapeutics Inc., a Princeton biotechnology company, bought about $186,000 worth of raw materials and clinical supplies from businesses controlled by shareholder Johnson & Johnson of New Brunswick, Barrier reported in a filing with the Securities & Exchange Commission. Princeton-based Barrier plans to hold its annual meeting June 6 at its corporate headquarters. -- Jonathan Berr
